Dimerix is increasingly de-risking its commercial path via:
Global licensing strategy (regional commercialization outsourced),
Clinical progress (Phase 3 nearing key milestone),
Non-dilutive funding (upfronts, milestones, R&D rebates).
If Phase 3 data is positive, DXB could unlock significant value. Near term, watch for:
Japan trial site initiation (AU$4.1M milestone)
Ongoing patient dosing completion
Interim data results in Q3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
51.5¢ |
Change
0.005(0.98%) |
Mkt cap ! $300.1M | |||
| Open | High | Low | Value | Volume |
| 51.0¢ | 51.5¢ | 50.0¢ | $256.5K | 506.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 32288 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 51.5¢ | 56707 | 4 |
View Market Depth
| Last trade - 10.51am 17/06/2025 (20 minute delay) ? |
| DXB (ASX) Chart |